Phase 3 COPD Trial, Recruiting NCT07177339 Sponsor: GlaxoSmithKline Condition: COPD
Back to Copd

Phase 3 COPD Trial, Recruiting

NCT07177339
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men, or women who meet specific eligibility criteria set by the trial site
  • People who have a higher-than-normal level of a type of white blood cell called eosinophils, measured through a blood test
  • People who have been diagnosed with moderate to severe COPD for at least one year, confirmed by specific breathing test results
  • People who have had exactly one moderate COPD flare-up (worsening of symptoms) in the past 12 months, plus at least one additional risk factor for future flare-ups — such as significant breathlessness, a high COPD symptom score, reduced lung function, or a long-term chesty cough with mucus
  • People who are current or former cigarette smokers with a smoking history of at least 10 pack-years (confirm with trial site for how this is calculated)
  • People who have been using two or three inhaler medications together for at least 3 months, as assessed by the treating doctor
  • People with a body mass index (BMI) of 16 or above

Who may not be able to join:

  • People whose main lung condition is something other than COPD, as judged by the treating doctor
  • People who currently have, or have previously been diagnosed with, asthma (though people whose childhood asthma fully resolved before age 18 and has not returned may still be considered)
  • People with other significant lung diseases where COPD is not the primary diagnosis
  • People who have had more than one moderate flare-up, or any severe flare-up, of COPD in the 12 months before the first visit
  • People who have had pneumonia, a COPD flare-up, or a lower respiratory tract infection in the four weeks before the first visit
  • People who have previously had, or are planning to have, lung volume reduction surgery or a similar procedure
  • People currently in the active phase of a pulmonary rehabilitation programme within four weeks before the first visit
  • People who need a breathing support machine (such as BiPAP or CPAP) due to high carbon dioxide levels in their blood
  • People who need continuous supplemental oxygen because of their COPD

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: GSK Clinical Trials, GlaxoSmithKline

Phone: 877-379-3718

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
20 October 2025
Est. completion
2 November 2029

Where this trial is recruiting

🇨🇳 China 🇺🇸 United States

Primary endpoints

Annualized Rate of Moderate/Severe Exacerbations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov